Clinical Trial Budgeting Software Prototype Using AI

(Please drop a comment or reach out if you would like to discuss the development of this concept, exchange ideas, validate assumptions, or explore potential collaboration opportunities.)

Over the last weeks, I have been experimenting with AI-assisted development platforms such as Codex and Base44 to explore whether integrated clinical trial budgeting and operational planning concepts can now be prototyped much faster than traditionally possible with multiple disconnected systems.

As an educational proof-of-concept, I used publicly available clinical trial protocol examples to generate prototype Clinical Trial Budgeting and Project Management environments (links below).

The broader goal is not to create a validated production system at this stage, but rather to explore whether a lightweight educational platform could eventually help research groups, startups, CROs, and biotech teams:

• estimate study budgets,
• evaluate operational feasibility,
• understand budget drivers,
• model resource requirements,
• and visualize operational complexity earlier in the planning process.

The current prototype explores concepts such as:

1. Creating and modifying protocol-derived work units, including classification into contracted scope and Out-of-Scope (OOS) activities
2. Drilling down from high-level assumptions into operational detail:
   site-level planning, visit schedules, resource allocation, employee roles, and unit composition updates (standard vs. study-specific assumptions)
3. Generating linked operational outputs such as:
   budget grids, resource plans, contract-related structures, and project plans
4. Exploring governance concepts where operational units may eventually be linked to supporting evidence of completed work (for example visit reports or TMF-related documentation)
5. Estimating planned effort and operational workload required to complete study activities, including earned value-style concepts
6. Exploring study metrics and operational oversight approaches connected to workload and delivery status

What is particularly interesting is how functional these AI-generated prototypes already appear at an early exploratory stage.

Of course, any budgeting logic, assumptions, calculations, or operational recommendations would require careful validation against real-world studies, operational practice, governance requirements, and financial controls before any practical use.

One especially interesting direction may be comparing traditional Excel-based budgeting approaches with AI-assisted relational database and rule-driven systems.

If budgeting logic can already be implemented in spreadsheets, similar logic may potentially be implemented in structured relational systems with:

• more traceable assumptions,
• reusable rule frameworks,
• integrated operational planning,
• and improved visibility into how budgets are constructed and maintained.

The next step will likely involve continuing similar experiments using:

• @Base44,
• Oracle APEX,
• Power BI-based offline environments,
• and other educational prototyping approaches.

This remains an early-stage exploratory concept and should not be interpreted as a validated budgeting methodology or operational system.

However, the speed at which these concepts can now be tested, modified, and visualized using modern AI-assisted development approaches is quite remarkable.

If anyone is interested in discussing the concept, validating assumptions, contributing ideas, or exploring potential student/research collaboration opportunities, I would be very interested to connect.

Links and References

1. System prompt:
   https://github.com/DmitryHubPM/CPMS/blob/main/base44-prompt.md
2. Codex prototype:
   https://dmitryhubpm.github.io/CPMS/
3. Base44 prototype:
   https://clinico-plan-pro.base44.app
4. Publicly available protocol document referenced solely for educational and illustrative prototype purposes:
   https://dac-trials.org/wp-content/uploads/PNE-Pneumonia-2019-Alexander-LEAP2.pdf

Can AI Develop a Clinical Trial Budget Calculator?

Over the last months, I have been experimenting with whether modern AI-assisted development platforms can support the creation of structured operational and budgeting systems for clinical research.

One interesting experiment was the development of a simplified Clinical Trial Budget Calculator (CTBC) using the AI-assisted platform Base44.

The result is a working prototype application:

https://ledger-flow-76f4f135.base44.app/

(The application currently requires free authorization via Google or email.)

Clinical Trial Protocol and ChatGPT: Why Can’t You Upload It?

Many newcomers to clinical research ask a surprisingly modern question:

If generative AI can read long documents, summarize complexity, detect inconsistencies, build schedules, and help teams prepare faster: - why can’t project teams simply upload a clinical trial protocol?

What Is an ICF in Clinical Research?

 A Practical Guide for Students and Future Trial Participants

Clinical research uses many technical abbreviations, but few are as important as ICF, which stands for Informed Consent Form. Although often described simply as “a form to sign,” this is only part of the picture. In reality, the ICF is one of the core ethical safeguards in modern human research.

An Informed Consent Form is the document, and more importantly, the communication process, through which a potential participant receives information about a clinical study before deciding whether to join. It is intended to help a person understand what the study is about, what participation may involve, what risks may exist, what possible benefits may or may not occur, and what rights remain with the participant throughout the study.

In simple terms, the ICF is where science meets human choice.

Examples of Informed Consent Forms (ICF)

Students often ask what an actual Informed Consent Form looks like in practice. Below are several publicly available examples and templates for educational review. These documents help illustrate structure, tone, and the type of information participants usually receive.

1. Real Clinical Trial ICF Example – ClinicalTrials.gov

Public example of an informed consent form filed in connection with a registered study: Sample Clinical Trial ICF PDF ( PDF: https://cdn.clinicaltrials.gov/large-docs/95/NCT01873495/ICF_001.pdf)

What Is a Contract Research Organization (CRO)? Role in Clinical Trials and Future Trends

Clinical trials are essential for developing new medicines, but they require coordination across many different participants, including sponsors, hospitals, and regulatory authorities. One of the most important—yet often less understood—participants in this process is the Contract Research Organization (CRO).

A Contract Research Organization is a company that provides services to support the planning, management, and execution of clinical trials. CROs play a key role in helping sponsors run studies efficiently, especially when trials involve multiple countries, sites, and complex regulatory requirements.

What Does a Contract Research Organization Do?

Lessons Learned in Project Management: Why They Fail and How to Make Them Work

Lessons learned help improve project outcomes, but often fail in practice. Learn how to classify issues, define ownership, and ensure real operational change.

What Are “Lessons Learned”?

From Dialogue to Noosphere: The Evolutionary Role of Generative AI in Idea Formation

(Summary of my recent chat with GPT)

Introduction

Generative AI changes how ideas are developed, not by replacing knowledge creation, but by altering how ideas are assembled, refined, and connected. Interaction no longer depends entirely on direct discussion, access to specific authors, or long feedback cycles. Instead, a generative system enables continuous reformulation of thoughts, exposure to missing elements, and structured expansion.

This shift introduces a different constraint. Previously, the development of ideas was limited by access to interaction. With generative AI, interaction becomes continuously available, but its structure is mediated. As a result, ideas can evolve faster, yet they may also converge in systematic ways.

From Paper to Integrated Data Flow? (PDC->MDC->EDC?)

A short dream about the future of clinical trials

Sometimes it feels like clinical trials are very modern and very digital.
We have electronic systems, dashboards, remote monitoring, and cloud platforms.

But if we look closely at how clinical data actually moves, the story is more interesting.

It is not really a story about paper becoming electronic. It is a story about manual transcription slowly disappearing.

You could describe the evolution of clinical trials data capture in four stages:

PDC → MDC → EDC → IDF

And we are probably somewhere between stage 2 and stage 3.

Stage 1. PDC (Paper Data Capture)

In the beginning, everything was paper.

The investigator wrote data in the medical record.
Then the site copied the data into a paper CRF.
Then someone at the sponsor or CRO entered the paper CRF into a database.

So the data was written three times:

1. Source document
2. Paper CRF
3. Database

Paper was not the problem.
Transcription was the problem.

Stage 2. MDC (Double-Manual Data Capture)

Then came EDC systems.

Paper CRFs disappeared, but something interesting happened:
The process did not become electronic — it became manual data entry into an electronic system.

The workflow now looked like this:

• Data written in source
• Site manually enters data into EDC
• CRA compares source vs EDC (SDV)
• Queries are raised
• Corrections are made
• Emails are sent
• Monitoring reports are written

So the system was electronic, but the process was still manual transcription.

You could argue that many trials today are still in the Manual Data Capture era.

Stage 3. EDC (True Electronic Data Capture)

True electronic data capture means something different:
Data is created electronically at the source and transferred directly into the database.

Examples:

• ePRO
• Wearables
• Devices
• Lab data transfers
• eSource
• EMR integrations

In this world, data is not copied anymore.
It is generated digitally and transferred automatically.

If there is no transcription, then many traditional processes change:

• Less SDV
• Fewer queries
• More central monitoring
• More data analytics
• Monitoring becomes process and risk review instead of document comparison

We are moving in this direction, but we are not fully there yet.

Stage 4. IDF (Integrated Data Flow)

The final stage is not just electronic data capture, but integrated data flow.

In this model:

• Data is captured once
• Systems are connected
• Quality metrics are generated automatically
• Escalations are workflow-driven, not email-driven
• Documentation is generated from the process itself
• Databases, TMF, CTMS, and quality systems are connected

At that point, clinical trials will not be document-driven anymore.
They will be process- and data-flow-driven.

This is probably the direction the industry is slowly moving toward.

---

Summary Table

Stage	Name	How data is captured	Transcription	Main control
PDC	Paper Data Capture	Paper CRF	Double manual	SDV & data entry checks
MDC	Manual Data Capture	Manual entry into EDC	Single manual	SDV, queries, monitoring
EDC	True Electronic Data Capture	Digital source → database	No transcription	Edit checks, central monitoring
IDF	Integrated Data Flow	Connected systems	No transcription	Process control & analytics

---

One Important Thought

If we look at this evolution, the biggest change is not paper vs electronic.

The biggest change is this:

Clinical trials are slowly moving from transcription-based data collection to data-flow-based data collection.

And maybe one day, SDV will be remembered as something that existed mainly because humans had to copy data from one system into another?

EMA Data Quality Framework for Medicines Regulation

The European regulatory environment has recently introduced a dedicated framework specifically addressing data quality in the context of medicines regulation and the use of real-world data. This framework is documented in the Data Quality Framework for EU Medicines Regulation - Application to Real-World Data, published by the European Medicines Agency:

https://www.ema.europa.eu/en/documents/other/data-quality-framework-eu-medicines-regulation-application-real-world-data_en.pdf

Making Unaccounted Costs Accountable in Clinical Research

Clinical trials operate under strict timelines, regulatory requirements, and complex coordination between sponsors, CROs, sites, and vendors. When delays occur or issues arise, project teams often resolve problems by working longer hours rather than by adjusting timelines, budgets, or processes.

In many organizations, a standard working day is approximately eight hours. However, Clinical Research Associates, Project Managers, and other clinical operations staff may regularly work ten or more hours per day, especially during critical study phases.

If only eight hours are recorded in time sheets while ten hours are actually worked, two hours per day become unaccounted operational effort.

Individually, this may appear minor. Over the duration of a clinical trial, the financial impact can be substantial.

Financial Example: Unaccounted Hours Over a Project Duration

Hidden, Absorbed, and Unaccounted Costs in Clinical Trials

Clinical trials are widely recognized as expensive and complex projects. Budget discussions usually focus on visible cost elements such as labour fees, investigator grants, site payments, vendor contracts, other passthorough. These costs are clearly documented in study budgets and contracts and are typically tracked through project accounting systems.

However, the real operational cost of clinical trials often extends beyond these visible budget lines. During study execution, additional effort frequently arises from inefficient processes, fragmented systems, and operational challenges that require extra coordination by project teams.

Some of this work eventually appears in project effort reports. Some of it is absorbed by organizations when project budgets are exceeded. And some effort may never be formally recorded at all.

To illustrate this situation, it can be useful to distinguish between four different categories of costs in clinical trial operations: visible costs, hidden costs, absorbed costs, and unaccounted costs.

What Are AI Agents and How Can They Help Optimize Clinical Trial Operations

Removing duplication in clinical trial operations could significantly reduce costs and increase research capacity. One emerging technology that may help enable this transformation is the concept of AI agents. But what exactly are AI agents, and how could they improve clinical trial operations?

What are AI agents?

An AI agent is a software system designed to perform tasks autonomously based on defined goals, available data, and operational rules.

Traditional software typically executes predefined commands. AI agents, in contrast, can interpret information, analyze context, and trigger actions within complex workflows.

In practical terms, AI agents can:

• interpret structured information

• coordinate operational processes

• trigger workflows across systems

• monitor data and identify anomalies

• generate reports or documentation

Rather than acting only as databases or static tools, AI agents can function as digital operators that help coordinate processes and information flows.

Why clinical trial operations are suitable for AI agents

Could Clinical Trial Costs Be Reduced by Half?

Could Halving Clinical Trial Costs Double the Benefits of Clinical Research?

Clinical trials are essential for developing new therapies, but they are also widely known to be expensive. Conducting a single clinical study often requires large budgets, complex coordination, and significant operational infrastructure.

But this raises an important question: How much of the cost of clinical trials is driven by scientific requirements—and how much is driven by operational complexity?

Clinical trials must support patient care, medical procedures, and the evaluation of investigational treatments. These elements are essential and cannot be eliminated. However, a substantial portion of clinical trial budgets is also devoted to coordinating processes, documenting activities, reconciling information across systems, and managing regulatory workflows.

In this sense, clinical trials are not only scientific investigations. They are also large operational systems.

Understanding how these systems are organized may reveal opportunities to improve efficiency without compromising scientific quality.

Validation vs Usability in Clinical Trial Systems: Balancing Reactive Control and Preventive Design

Clinical research operates within a tightly regulated environment in which digital systems are subject to rigorous validation requirements. Data capture platforms, trial master file systems, safety databases, and financial tracking tools must demonstrate reliability, traceability, and compliance with Good Clinical Practice principles. Validation is foundational. Without it, data integrity and participant safety cannot be assured.

Yet validation alone does not guarantee that a system supports efficient and stable trial execution. A platform may perform exactly as specified under documented test conditions, and still generate friction in day-to-day operations. This distinction between validation and usability is rarely explored explicitly, but it carries structural implications for quality management in clinical research.

Under frameworks such as ICH E6(R2) and ICH E6(R3), computerized systems must be fit for purpose and maintain data integrity throughout the study lifecycle. The regulatory emphasis is appropriately placed on reliability, auditability, and control. However, “fit for purpose” can be interpreted narrowly as technical compliance, or more broadly as operational adequacy. The difference matters.

Validation confirms that a system behaves as intended according to predefined requirements. It answers the question: does the software function correctly under documented scenarios? 

Usability, by contrast, addresses whether real users can execute complex workflows efficiently, consistently, and without excessive workaround behavior. It asks: does the system support how work is actually performed in a clinical trial?

Is Clinical Trial Software Truly Fit for Purpose?

Clinical research today operates within a dense digital ecosystem. Electronic data capture systems, trial master file platforms, safety databases, project portfolio tools, and financial tracking solutions collectively form the infrastructure of modern study execution. From a technical standpoint, these systems are validated, cloud-enabled, and increasingly interoperable. Yet a more fundamental question often remains insufficiently examined: does the existing software landscape actually cover the functionality required by the study it supports?

The concept of “fit for purpose” is frequently used in regulated environments, particularly under frameworks such as ICH E6(R2) and ICH E6(R3). Within this context, systems must ensure data integrity, reliability, traceability, and appropriate documentation. However, regulatory compliance alone does not automatically imply operational adequacy. A system may meet validation standards and still fall short in representing the real operational complexity of a study.

Clinical Trial Automation: The Naming Conventions Challenge

Is cross-system clinical trial automation failing not because workflows cannot be executed, but because protocol terminology cannot be interpreted consistently across systems and clinical studies?

Discussions about automating clinical trials often focus on advanced technologies such as workflow engines, interoperability standards, and AI/ML. In practice, cross-system automation most often breaks much earlier, at a far more basic level: inconsistent naming conventions. 

Clinical protocols are written in natural language, where the same term can legitimately carry different meanings depending on study design, therapeutic area, or regulatory intent. Software systems, by contrast, assume that identifiers are stable, explicit, and unambiguous. This mismatch creates friction long before questions of execution logic or governance arise.

Several academic and industry initiatives have proposed encoding protocol elements, such as eligibility criteria, visits, milestones, consent states, into structured system logic. While technically feasible, these efforts consistently encounter a semantic problem: the protocol terms being encoded do not have a single, invariant meaning. Instead, their interpretation is context-dependent and often only becomes clear when the protocol is implemented across multiple systems such as CTMS, EDC, TMF, and finance. Automation struggles not because systems cannot execute logic, but because they cannot reliably infer what a term is supposed to mean.

Blockchain to Clinical Trial Automation – What Are the Obstacles?

Why promising concepts have not translated into practical implementation? Lessons Learned.

The idea of using blockchain to automate clinical trials emerged from a compelling analogy: if financial contracts can be expressed as executable smart contracts, why not clinical protocols? 

Project Management and Modular Outsourcing

Platforms, GenAI, and modular services. How can this impact Project Management? 

Work organization is evolving across many knowledge-intensive industries. Digital platforms, GenAI-assisted production, and global access to qualified specialists are changing how services are offered, priced, and evaluated. This development is visible even in domains traditionally characterized by strong regulation and institutional structures, like clinical research. Rather than asking whether regulated projects are “moving” to open platforms, a more precise question is:

Swissmedic Submissions and Project Timelines: Why Approval Speed Determines Your Study Start

Clinical trial timelines in Switzerland are tightly linked to the efficiency of submissions to Swissmedic.

Delays at this stage do not remain confined to regulatory milestones. They cascade into site activation, contracts, budgets, and overall project duration.

From a project-management perspective, Swissmedic approval is frequently on the critical path. Even minor, avoidable issues (missing annexes, outdated guidance, inconsistent documents) can postpone study start by weeks or months.

Longevity as a Project

What changes if we consider life as a project?

Projects fail rarely because of one catastrophic event. They fail because small deviations accumulate, risks go unnoticed, and performance is not tracked against expectations. Aging may follow a similar pattern.

Instead of asking “How do we defeat aging?”, we can ask a different question:

What if we consider life as a long-running project, and manage it using basic project control logic?

This reframing does not promise immortality. It proposes something more modest and potentially more useful: governance of healthspan over time.

Project management analogy: Planned, Actual, and Longevity Value

Innovative Mobile Platforms for Clinical Research and Evidence Generation

Advances in mobile technology have opened new pathways for clinical research that go beyond traditional site-centric models. Mobile apps now play a growing role in study visibility, participant engagement, and data collection, both within regulated clinical trials and in healthy-population research.

Rather than replacing clinical trial systems, these platforms operate at a different layer:
they connect people to research, standardise how participation occurs, and enable more continuous, real-world data capture. Over time, this may support more structured datasets, easier study access, and more reliable evidence for analysis and decision-making.

Below are two groups of mobile platforms illustrating this shift.

Mobile Platforms Supporting Clinical Trial Participation

(Patient-facing, trial-specific apps)

Science 37 — Studies App

Focus: Decentralized and hybrid clinical trials

Science 37’s Studies App allows participants to discover, consent to, and take part in clinical trials remotely. The platform reduces dependence on physical sites and lowers participation barriers, particularly for patients who would otherwise not have access to research centers.

• Website: https://www.science37.com

• Google Play: https://play.google.com/store/apps/details?id=com.science37.mobile

"Fit for Purpose" in Clinical Research

One trial, one purpose or many stakeholder perspectives?

The expression “fit for purpose” appears 14 times in **ICH GCP ICH E6(R3). This repetition is not accidental. It signals a deliberate regulatory shift away from rigid, one-size-fits-all compliance toward a more contextual, risk-based understanding of quality, proportionality, and oversight in clinical research.

At the same time, the phrase itself is deceptively simple. According to the Cambridge Dictionary, fit for purpose means:

“Suitable and good enough to do what it is intended to do.”

Fit for Purpose in ICH GCP (R3)

Within ICH GCP E6(R3), fit for purpose is used to describe a wide range of elements, including trial processes, quality management systems, oversight mechanisms, data handling approaches, and supporting technologies. Across all these contexts, the underlying principle is consistent: systems and processes should be appropriate for their intended use, proportionate to risk, and focused on what truly matters for participant safety and reliable decision-making.

"Quality by Design" in Clinical Trials

What is Quality by Design according to ICH GCP E6(R3)? 

E6(R3) Good Clinical Practice (GCP) places Quality by Design as a a key and recurring principle across the guideline. The concept is introduced in the context of clinical study design, risk identification, and planning, and is reinforced at multiple points throughout the document as follows:

FDA Warning Letters to Investigators: Tutorial Examples

FDA warning letters are most often associated with manufacturing or product-related issues, but they can also be issued directly to clinical investigators when significant regulatory concerns are identified during inspections. 

These letters are typically issued months after the underlying events, following:

• an on-site inspection,

• documented observations,

• and review of written responses provided by the investigator or site.

As a result, a warning letter may appear long after the clinical activity in question has already concluded.

Here are 2 examples from December 2025:

• Example 1  - https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purushothaman-damodara-kumaran-md-721325-12222025
• Example 2 - https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/devalingam-mahalingam-md-phd-721145-12112025

What such letters generally indicate

The Ten "Commandments" of AI in Drug Development

Guiding Principles of Good AI Practice in Drug Development, January 2026 (https://www.fda.gov/media/189581/download)

In January 2026, the U.S. Food and Drug Administration, together with international regulatory partners, published ten principles for Good AI Practice in Drug Development:

1. Human-centric by design

2. Risk-based approach

3. Adherence to standards

4. Clear context of use

5. Multidisciplinary expertise

6. Data governance and documentation

7. Model design and development practices

8. Risk-based performance assessment

9. Life cycle management

10. Clear, essential information

These principles are presented as a foundation for further work rather than a finalized implementation framework. They describe what regulators consider important when AI is used to generate evidence across the drug product life cycle, without defining how these expectations should be met in specific technical or organizational settings.

At this stage, the document is intentionally high-level. Practical interpretation and operationalization will likely evolve through continued dialogue between regulators, industry, standards bodies, and technology developers.

https://www.raps.org/news-and-articles/news-articles/2026/1/ema-fda-issue-joint-ai-guiding-principles-for-drug

Familiar Concepts in a New Context

Many of the principles may sound familiar to professionals working with established clinical trial systems such as EDC, CTMS, or eTMF platforms. Concepts like risk-based approaches, lifecycle management, data governance, documentation, and adherence to standards are already part of everyday regulatory practice.

What appears different is not the concepts themselves, but the context in which they are now being emphasized. When AI is introduced, familiar expectations are applied to technologies that may behave differently from traditional, rule-based systems. This naturally raises questions about interpretation rather than compliance.

An Open Question Worth Considering

One possible way to read the guidance is to view it as an invitation to reflect:

• Which of these principles are already well understood and operationalized in existing clinical systems?

• Where might AI introduce additional considerations that are less explicit in traditional software development?

• How might established practices evolve as systems move from deterministic behavior toward more adaptive or probabilistic approaches?

These are not questions with immediate or universal answers. They depend heavily on context, use case, system design, and regulatory interaction.

Early Guidance, Not Final Instruction

Importantly, the FDA document does not claim to resolve these questions. Instead, it sets a shared reference point for future discussion and alignment. The absence of technical detail should not be read as a gap, but as recognition that good practice in this area is still emerging and will require time, experimentation, and collaboration to mature.

For now, the principles serve as a common language, useful for orientation, internal discussion, and education.

Closing Note

As AI continues to enter regulated environments, documents like this are likely to be revisited, refined, and expanded. Understanding them as living guidance, rather than fixed rules, may be the most appropriate way to approach them at this stage.

For readers involved in clinical systems, software development, or regulatory oversight, the principles offer a structured way to think about AI, without yet demanding definitive answers.

Disclaimer: This post reflects an educational interpretation of publicly available regulatory guidance and does not constitute regulatory or legal advice.

What a 50% Increase in FDA CDER Warning Letters Tells Us About Quality, Oversight, and System Pressure

According to remarks reported by the Regulatory Affairs Professionals Society, the FDA Center for Drug Evaluation and Research (CDER) issued 50% more warning letters in fiscal year 2025 than in the previous year. This is a notable increase and suggests a change in enforcement activity that warrants closer examination. Whether this reflects a shift in regulatory posture, changes in industry behavior, or increased scrutiny of emerging areas remains an open question.

Rather than treating this figure purely as a headline about enforcement intensity, it is useful to consider what such an increase may indicate about where regulatory attention is currently focused and how oversight adapts as technologies, business models, and supply chains evolve.

Enforcement volume as a signal, not just an outcome

Warning letters are often viewed as the final step in regulatory enforcement. From a systems perspective, they can also be understood as lagging indicators. By the time a warning letter is issued, inspections have occurred, observations have been documented, and responses have been reviewed. Escalation typically reflects a judgment that identified issues were not adequately addressed.

A sharp increase in warning letters therefore raises a broader question:

are regulators encountering more instances of noncompliance, or are they applying closer scrutiny to areas where compliance expectations are still being interpreted and tested?

Innovative Software Solutions in Clinical Research

Clinical research software is often associated with large, enterprise platforms. Alongside these established systems, however, a growing group of specialized and innovation-focused solutions addresses specific pain points such as protocol planning, budgeting, recruitment, operational oversight, and documentation. These tools are frequently adopted as complements to core systems rather than replacements, particularly in regulated environments.

This overview highlights selected software providers that are commonly referenced in discussions about digital transformation in clinical research, with a focus on planning, feasibility, budgeting, and operational coordination.

Protocol Design, Planning, Budgeting and Feasibility

• Espero Health (Sweden) develops software focused on protocol-driven budgeting and feasibility assessment in clinical research. The platform emphasizes deriving cost and effort estimates directly from structured protocol activities and Schedule of Events assumptions, supporting transparency between clinical planning and financial oversight. Website: https://espero-health.com/

• Trials.ai was developed as a decision-support platform for data-driven clinical trial planning. Public information indicates a focus on analyzing historical trial data, literature, and protocol elements to support study design decisions. The company was later acquired and integrated into a larger life-sciences analytics organization, suggesting its capabilities are now embedded in enterprise-level offerings. Website: https://www.trials.ai/

• Risklick is a Switzerland-based company offering software to support structured clinical protocol development, particularly in regulated environments such as medical devices and clinical trials. Its solutions emphasize consistency, reuse of prior knowledge, and alignment with regulatory expectations during protocol authoring. Website: https://www.risklick.ch/, https://www.linkedin.com/company/risklick

• Condor Software provides solutions for clinical trial financial management, including budgeting, forecasting, and site payment processes. The platform focuses on improving transparency and alignment between clinical operations and financial oversight, an area often associated with manual reconciliation and fragmented workflows. Website: https://www.condorsoftware.com/, https://www.linkedin.com/company/condor-software-inc

• Clinical Maestro® by Strategikon is a clinical trial planning and intelligence platform designed to support feasibility assessment, operational forecasting, and data-driven decision-making during study design and portfolio planning. The software focuses on improving transparency and predictability prior to and alongside trial execution rather than replacing core operational systems. Website: https://strategikon.com/, https://www.linkedin.com/company/clinical-maestro/
  

  ProofPilot provides a digital protocol and workflow automation platform intended to reduce manual effort during trial setup and execution. Its emphasis is on standardization, traceability, and structured workflows rather than replacing existing operational systems. Website: https://www.proofpilot.com/, https://www.linkedin.com/company/proofpilot/

Recruitment, Engagement, and Matching

• Pathkey.AI was previously known as Opyl and has since repositioned its focus toward simulation-based clinical trial design and biostatistical validation.
  Website: https://opyl.netlify.app/, https://www.linkedin.com/company/pathkeyai/

• TrialX offers tools that help patients and clinicians identify suitable clinical trials based on eligibility criteria, with the goal of improving accessibility and reducing recruitment delays. Website: https://www.trialx.com/, https://www.linkedin.com/company/trialx/ 

• Hekma is a patient-centric, medical data science company located in San Francisco Bay Area that is dedicated to improving clinical trials and accelerating drug approval. Website: https://www.hekma.ai/, https://www.linkedin.com/company/hekma/

Documentation and Structured Knowledge

• Yseop provides software supporting structured medical and regulatory documentation, including clinical study reports and narratives. The platform emphasizes controlled language, consistency, and traceability—key requirements in regulated clinical environments.
  Website: https://yseop.com/, https://www.linkedin.com/company/yseop/
  

• Merative (formerly Truven Health Analytics, later part of IBM Watson Health) provides large-scale healthcare and real-world evidence analytics used across life sciences, payer, and outcomes research. Website: https://www.merative.com/truven, https://www.linkedin.com/showcase/truven-by-merative/about/

Quality and Regulatory Considerations

All software used in clinical research must operate within established quality and regulatory frameworks, particularly for studies conducted under FDA or EMA oversight. Regardless of innovation level, such tools are expected to support data integrity, audit trails, access control, and validation appropriate to their intended use. As a result, many innovative solutions are positioned as decision-support or planning layers, complementing validated core systems rather than replacing them.

Toward Future Software Evaluation

As digital transformation in clinical research continues, independent and experience-based software evaluation becomes increasingly relevant. Beyond feature descriptions, meaningful assessment requires understanding how tools integrate into operational workflows, quality systems, and regulatory constraints.

This blog aims to document and observe these developments over time. Future posts may explore individual solutions in more depth, focusing on use cases, limitations, and integration considerations, rather than promotional claims.

How to Access and Read FDA Warning Letters (A Practical Guide for a Tutorial)

FDA warning letters are publicly available and can be read in full. They are one of the most transparent regulatory resources for understanding how quality and compliance issues are identified and described by regulators.

Official FDA Warning Letter Repository

All FDA warning letters are published on the official FDA website:

👉 FDA Warning Letters Database
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

This repository is maintained by the U.S. Food and Drug Administration and is updated regularly.

How the repository is structured

On the FDA warning letters page, you can:

• Browse warning letters by year

• Filter by FDA center (e.g. drugs, biologics, devices)

• Search by company name

• Search by subject or keyword

Each entry links to a PDF or HTML letter issued directly by the FDA.

What to look for when reading a warning letter

For educational purposes, it is useful to read warning letters systematically rather than casually. Key sections to focus on include:

1. Inspection background
   Describes when and why the FDA inspection or review took place.

2. Observed violations
   Lists specific regulatory deficiencies, often referencing CFR sections.

3. Regulatory interpretation
   Explains why the FDA considers the findings significant.

4. Expected corrective actions
   Indicates what the FDA expects the organization to address.

5. Potential consequences
   Outlines possible enforcement actions if issues are not resolved.

Reading these sections helps build familiarity with how regulators reason, not just what rules exist.

Why warning letters are useful learning material

Unlike guidance documents, warning letters:

• reflect actual failures, not hypothetical scenarios,

• show how regulations are applied in practice,

• reveal recurring patterns across organizations and time,

• illustrate the link between operational decisions and regulatory outcomes.

For students of clinical research, quality, or project management, they offer insight into system-level weaknesses that are difficult to see in controlled examples.

Using warning letters responsibly

Warning letters should not be read as:

• judgments of intent,

• proof of misconduct beyond what is stated,

• or definitive conclusions about patient harm.

They should be read as regulatory signals: indicators that systems, processes, or controls did not perform as expected.

A suggested exercise (an illustration for learning)

A simple educational approach is to:

1. Select one warning letter from the FDA database.

2. Identify the main category of violation (e.g. GMP, clinical research, labeling).

3. Ask what project, process, or system failure likely contributed.

4. Consider what preventive controls could have reduced the risk.

This turns regulatory documents into learning artifacts, rather than compliance anecdotes.

Reducing Clinical Trial Complexity

What recent publications and reports are pointing to. Evidence and open questions.

Clinical trials are essential for evaluating the safety and efficacy of new therapies, but the operational and financial burden of modern trials has grown significantly over recent decades. Trials are becoming more complex, expensive, and difficult to execute. These often require elaborated protocol designs, extensive regulatory documentation, and multi-site coordination. All of which contribute to longer timelines and higher costs. Recent analyst commentary on the clinical trials industry highlights complexity as a core challenge limiting feasibility. https://www.clinicaltrialsarena.com/features/clinical-trials-challenges-expect-2025

At the same time, funding disruptions have had measurable impacts on clinical research feasibility. A study published in JAMA Internal Medicine reported that NIH grant terminations disrupted approximately 3.5 % of active federally funded clinical trials, affecting over 74,000 enrolled participants and resulting in significant lost funding. These kinds of funding cutbacks do not reflect scientific failure but rather resource constraints that force studies to halt or terminate early. https://www.ajmc.com/view/nih-grant-terminations-disrupt-1-in-30-clinical-trials-impacting-over-74-000-participants

Operational burden and complexity not only challenge sponsors financially but also increase the risk of failure for individual trials and patient safety. A broad literature review of why clinical trials fail identifies high operational and financial burden as one of the factors associated with trial discontinuation, alongside recruitment challenges and design issues. This evidence reinforces the idea that cost and complexity are practical constraints in trial implementation. https://pmc.ncbi.nlm.nih.gov/articles/PMC6092479/

In response to these challenges, researchers and industry groups have begun to develop tools and frameworks to measure and mitigate complexity. A 2025 methodological study introduced a protocol complexity tool that quantifies different aspects of a trial’s design (operational execution, regulatory burden, patient/site burden, etc.) and correlates complexity scores with key trial indicators such as site activation and recruitment timelines. The aim is to provide evidence-based simplification without compromising scientific or ethical standards. https://www.researchgate.net/publication/395032442_Development_of_a_protocol_complexity_tool_a_framework_designed_to_stimulate_discussion_and_simplify_study_design

Beyond individual tools, advocacy from researchers and consortia highlights broader systemic barriers, such as regulatory fragmentation and administrative burden, which can delay trial start-up and reduce feasibility, especially in multinational research contexts. For example, groups in the EU have called for regulatory alignment and reduced administrative complexity to support clinical research across member states, recognizing that procedural obstacles repeatedly delay studies and increase costs. https://eatris.eu/news/clinical-trial-community-seek-urgent-implementation-of-life-science-strategy-as-european-research-becomes-increasingly-endangered/ 

These strands of evidence do not claim that simplification alone will guarantee more lifesaving drugs, nor that reducing cost automatically improves scientific reliability, but they do support a conditional hypothesis: if a large share of current trial resources is consumed by procedural complexity and cost burden rather than core scientific evaluation, then reducing unnecessary complexity could make some studies more operationally feasible within existing budgets, possibly enabling a broader set of research questions to be pursued. https://zenodo.org/records/15651378 

Open question: Does reducing administrative and operational complexity without weakening scientific standards actually free up resources to support additional trials, and could that in turn accelerate meaningful clinical advances? This remains a continuing area of professional and methodological inquiry rather than a settled fact. Recent publications and tool development efforts suggest it is a practical, evidence-informed question worth exploring.

More on this topic in my earlier posts: 

1. Trial–Project Dualism: An Operational View https://www.project-owner.com/2025/12/trialproject-dualism-operational-view.html
2. Structuring Project Complexity: Reviewing Patents related to Project Management https://www.project-owner.com/2025/05/structuring-project-complexity.html
3. From Digitalization to Digital Transformation in Clinical Research https://www.project-owner.com/2025/07/from-digitalization-to-digital.html

Blogging in the GenAI Age: Why Writing May Still Matter in 2026

Blogging in 2026 looks questionable. Most people no longer read blogs and long posts. Information is searched, skimmed, or delegated to generative AI. Even thoughtful posts may attract little attention, while AI can generate fluent text instantly. Against this background, blogging no longer functions reliably as a communication channel. The relevant question is therefore not how to grow a blog, but whether blogging still serves a meaningful purpose.

One answer is epistemic. Blogging has increasingly become a way of documenting reasoning rather than broadcasting information. Generative AI produces language at scale, but it does not assess novelty, truth, or justification. It optimizes for plausibility, not for being right for the right reasons. When humans write carefully, make assumptions explicit, and acknowledge uncertainty, they leave traces of reasoning that are qualitatively different from synthetic text. Blogging, in this sense, preserves human judgment in public form.

This matters not only for readers, but also for the stability of AI systems. A 2024 Nature paper showed that when generative models are trained recursively on content produced by earlier models, performance degrades, diversity collapses, and errors reinforce over time. This phenomenon is known as model collapse. The study is not about blogs specifically, but it highlights a general mechanism: if new data increasingly lacks grounding in human experience, experimentation, and reasoning, systems become self-referential and brittle. The disappearance of human-authored reasoning from public spaces removes precisely the kind of epistemic input that synthetic systems cannot generate on their own.

At the same time, public writing and blogs can not be treated as reliable input. A 2024 ACM study examining Common Crawl, the largest public web dataset used in AI training, shows that blogs and other websites are included not because they are verified or correct, but because they are publicly available. Publication is treated as implicit permission. As a result, careful reasoning is mixed with speculation, error, and noise. Human-authored text may be necessary to prevent epistemic collapse, but availability alone does not guarantee quality.

Taken together, these findings suggest that the relationship between blogging and AI is unresolved rather than obsolete. Human writing may still be needed to introduce new experiences, reasoning paths, and interpretations into the public record, while the mechanisms for incorporating such material into AI systems remain an open challenge. How this exchange develops will be one of the more interesting questions to watch in 2026.

From the author’s perspective, epistemic motivations do not exclude pragmatic ones. Blogging can also support visibility or credibility, and in some cases writers become trusted one-person commentary channels through consistent, responsible publication. These outcomes are exceptions, but they show that epistemic and practical intentions can coexist.

Blogging in the GenAI age is therefore neither obsolete nor guaranteed to matter. Its value depends on whether human reasoning continues to be expressed publicly, even when attention is scarce and automation is easy.

References: 

• Shumailov, I., Shumaylov, Z., Zhao, Y. et al. AI models collapse when trained on recursively generated data. Nature 631, 755–759 (2024). https://doi.org/10.1038/s41586-024-07566-y 
• Stefan Baack. 2024. A Critical Analysis of the Largest Source for Generative AI Training Data: Common Crawl. In Proceedings of the 2024 ACM Conference on Fairness, Accountability, and Transparency (FAccT '24). Association for Computing Machinery, New York, NY, USA, 2199–2208. https://doi.org/10.1145/3630106.3659033